Karl Keegan

Karl is a highly regarded equity research analyst and heads up the HCLS team at Singer Capital Markets. With an academic background covering science (and finance, he has over 25 years' experience in the pharmaceutical and biotech industries, including extensive international financing, corporate development and Board roles. Kar has covered companies across the EU/US and Canada.